FDA Grants Accelerated Approval to Olaratumab for Treatment of Advanced Soft Tissue Sarcoma
The U.S. Food and Drug Administration (FDA) granted accelerated approval to olaratumab in combination with doxorubicin for the treatment of adult soft tissue sarcoma. The drug combination is approved for patients whose sarcoma cannot be cured with radiation or surgery and for whom doxorubicin is an appropriate treatment. Olaratumab works by blocking the platelet-derived growth factor (PDGF) receptor. Blocking this receptor may help slow or stop tumor growth.
Accelerated Approval is a program designed to speed the approval of promising drugs that treat serious or life-threatening illness and provide benefit over current treatments. This is the first new therapy to be approved by the FDA for the first line treatment of soft-tissue sarcoma in over 40 years. Read more from the ASCO Post here.
Learn more about adult soft tissue sarcoma on My PearlPoint.